1-20 of 202
Sherry A. Pierce
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Achievement of Measurable Residual Disease (MRD) Negativity Supersedes Treatment Intensity in Predicting the Outcome of Patients with Acute Myeloid Leukemia

Alexandre Bazinet, Tapan M. Kadia, Nicholas Short, Gautam Borthakur, Sa A Wang, Sanam Loghavi, Jeffrey L. Jorgensen, Keyur P. Patel, Courtney D. DiNardo, Naval Daver, Yesid Alvarado, Fadi Haddad, Sherry A. Pierce, Graciela M. Nogueras González, Abhishek Maiti, Michael Andreeff, Elias Jabbour, Marina Konopleva, Xuelin Huang, Hagop Kantarjian, Farhad Ravandi
Journal: Blood
Blood (2022) 140 (Supplement 1): 2267–2269.
https://doi.org/10.1182/blood-2022-162892
Published: 2022
Journal Articles

Phase I/II Study of Azacitidine (AZA) with Venetoclax (VEN) and Magrolimab (Magro) in Patients (pts) with Newly Diagnosed (ND) Older/Unfit or High-Risk Acute Myeloid Leukemia (AML) and Relapsed/Refractory (R/R) AML

Naval Daver, Jayastu Senapati, Abhishek Maiti, Sanam Loghavi, Tapan M. Kadia, Courtney D. DiNardo, Naveen Pemmaraju, Elias Jabbour, Guillermo Montalban-Bravo, Guilin Tang, Koji Sasaki, Gautam Borthakur, Musa Yilmaz, Joie Alvarez, Sherry A. Pierce, Graciela M. Nogueras González, Jing Ning, Ghayas C. Issa, Michael Andreeff, Hussein A Abbas, Farhad Ravandi, Guillermo Garcia-Manero, Hagop Kantarjian
Journal: Blood
Blood (2022) 140 (Supplement 1): 141–144.
https://doi.org/10.1182/blood-2022-170188
Published: 2022
Journal Articles

Clinical Outcomes and Impact of Therapeutic Intervention in Patients (pts) with Acute Myeloid Leukemia (AML) with Recurrence of Measurable Residual Disease (MRD) after Achievement of MRD-Negative Remission

Walid Macaron, Farhad Ravandi, Tapan M. Kadia, Courtney D. DiNardo, Ghayas C. Issa, Naval Daver, Sa A Wang, Jeffrey L. Jorgensen, Keyur Patel, Sanam Loghavi, Marina Konopleva, Musa Yilmaz, Elias Jabbour, Abhishek Maiti, Hussein A Abbas, Elizabeth J Shpall, Uday R Popat, Gheath Alatrash, Sherry A. Pierce, Hagop Kantarjian, Nicholas Short
Journal: Blood
Blood (2022) 140 (Supplement 1): 543–545.
https://doi.org/10.1182/blood-2022-156955
Published: 2022
Journal Articles

Outcomes of Chronic Myeloid Leukemia with No Major Molecular Response within 2 Years of Tyrosine Kinase Inhibitor Therapy

Aram Bidikian, Hagop Kantarjian, Ghayas C. Issa, Farhad Ravandi, Guillermo Garcia-Manero, Gautam Borthakur, Tapan M. Kadia, Naval Daver, Nitin Jain, Naveen Pemmaraju, Courtney D. DiNardo, Fadi Haddad, Sherry A. Pierce, Elias Jabbour, Koji Sasaki
Journal: Blood
Blood (2022) 140 (Supplement 1): 9626–9628.
https://doi.org/10.1182/blood-2022-167232
Published: 2022
Journal Articles

RAS Pathway Mutations Are Associated with Progression after Hypomethylating Agent Therapy in Chronic Myelomonocytic Leukemia

Guillermo Montalban-Bravo, Faezeh Darbaniyan, Kelly S. Chien, Danielle Hammond, Rashmi Kanagal-Shamanna, Tapan M. Kadia, Courtney D. DiNardo, Naval Daver, Farhad Ravandi, Elias Jabbour, Naveen Pemmaraju, Nicholas Short, Koichi Takahashi, Zeev E. Estrov, Sherry A. Pierce, Hagop Kantarjian, Guillermo Garcia-Manero
Journal: Blood
Blood (2022) 140 (Supplement 1): 4036–4038.
https://doi.org/10.1182/blood-2022-170069
Published: 2022
Journal Articles

A Phase I Open Label Study of Fostamatinib, a SYK Inhibitor, in Patients with Lower-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia

Guillermo Montalban-Bravo, Gautham Borthakur, Kelly S. Chien, Danielle Hammond, Rajani K Medury, Jane Waukau, Sherry A. Pierce, Hagop Kantarjian, Guillermo Garcia-Manero
Journal: Blood
Blood (2022) 140 (Supplement 1): 9816–9817.
https://doi.org/10.1182/blood-2022-170185
Published: 2022
Journal Articles

Genomic Evolution of Patients with Myelodysplastic Syndrome after Hypomethylating Agent Failure

Kelly S. Chien, Kunhwa Kim, Ziyi Li, Rashmi Kanagal-Shamanna, Faustine Ong, Guillermo Montalban-Bravo, Tapan M. Kadia, Elias Jabbour, Naveen Pemmaraju, Danielle Hammond, Nicholas Short, Farhad Ravandi, Yesid Alvarado, Sherry A. Pierce, Xiao Qin Dong, Hui Yang, Yue Wei, Irene Ganan-Gomez, Simona Colla, Hagop Kantarjian, Guillermo Garcia-Manero
Journal: Blood
Blood (2022) 140 (Supplement 1): 9773–9775.
https://doi.org/10.1182/blood-2022-169213
Published: 2022
Journal Articles

A Phase I/II Study of Seclidemstat, an LSD1 Inhibitor, and Azacitidine for Patients with Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia

Guillermo Montalban-Bravo, Courtney D. DiNardo, Nicholas Short, Tapan M. Kadia, Farhad Ravandi, Kelly S. Chien, Joby Joseph, Jane Waukau, Sherry A. Pierce, Hagop Kantarjian, Guillermo Garcia-Manero
Journal: Blood
Blood (2022) 140 (Supplement 1): 9771–9772.
https://doi.org/10.1182/blood-2022-170138
Published: 2022
Journal Articles

Outcome of Third-Line Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia in Chronic Phase: A Propensity Score Analysis

Elias Jabbour, Koji Sasaki, Ghayas C. Issa, Fadi Haddad, Guillermo Garcia-Manero, Tapan M. Kadia, William G. Wierda, Musa Yilmaz, Courtney D. DiNardo, Jeffrey Skinner, Naveen Pemmaraju, Sara E Dellasala, Sherry A. Pierce, Jorge E. Cortes, Hagop Kantarjian
Journal: Blood
Blood (2022) 140 (Supplement 1): 809–811.
https://doi.org/10.1182/blood-2022-169772
Published: 2022
Journal Articles

More Than Ten Years Follow-up of Frontline Tyrosine Kinase Inhibitor Therapy in Patients with Chronic Myeloid Leukemia

Fadi Haddad, Koji Sasaki, Ghayas C. Issa, Kunhwa Kim, Jeffrey Skinner, Sara E Dellasala, Yesid Alvarado, Alessandra Ferrajoli, Tapan M. Kadia, Musa Yilmaz, Naveen Pemmaraju, Guillermo Garcia-Manero, Sherry A. Pierce, Elias Jabbour, Hagop Kantarjian
Journal: Blood
Blood (2022) 140 (Supplement 1): 3897–3899.
https://doi.org/10.1182/blood-2022-168604
Published: 2022
Journal Articles

Prognostic Model of Transformation to Blast Phase in Patients with Chronic Myeloid Leukemia

Alex Bataller, Koji Sasaki, Elias Jabbour, Ghayas C. Issa, Fadi Haddad, Jeffrey Skinner, Sara E Dellasala, Guillermo Garcia-Manero, Sherry A. Pierce, Hagop Kantarjian
Journal: Blood
Blood (2022) 140 (Supplement 1): 3895–3896.
https://doi.org/10.1182/blood-2022-164924
Published: 2022
Journal Articles

Uproleselan Added to Cladribine Plus Low Dose Cytarabine (LDAC) in Patients with Treated Secondary Acute Myeloid Leukemia (TS-AML)

Emmanuel Almanza Huante, Hagop Kantarjian, Kelly S. Chien, Courtney D. DiNardo, Nicholas Short, Abhishek Maiti, Guillermo Montalban-Bravo, Naval Daver, Jitesh D. Kawedia, Kayleigh Bowie, Sherry A. Pierce, Farhad Ravandi, Marina Konopleva, Guillermo Garcia-Manero, Tapan M. Kadia
Journal: Blood
Blood (2022) 140 (Supplement 1): 3344–3346.
https://doi.org/10.1182/blood-2022-169670
Published: 2022
Journal Articles

Phase 2 Study of ASTX727 (cedazuridine/decitabine) Plus Venetoclax in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) or Previously Untreated, Elderly Patients with AML Unfit for Chemotherapy

Tareq Abuasab, Guillermo Garcia-Manero, Nicholas Short, Yesid Alvarado, Ghayas C. Issa, Rubiul Islam, Abhishek Maiti, Musa Yilmaz, Nitin Jain, Lucia Masarova, Steven M. Kornblau, Elias Jabbour, Naveen Pemmaraju, Guillermo Montalban-Bravo, Sherry A. Pierce, Courtney D. DiNardo, Tapan M. Kadia, Naval Daver, Marina Konopleva, Hagop Kantarjian, Farhad Ravandi
Journal: Blood
Blood (2022) 140 (Supplement 1): 3324–3326.
https://doi.org/10.1182/blood-2022-158566
Published: 2022
Journal Articles

Allogeneic Hematopoietic Stem Cell Transplantation in Older Patients with Acute Myeloid Leukemia: Analysis of Outcomes and Contemporary Trends Spanning 10 Years

Alexandre Bazinet, Hagop Kantarjian, Naszrin Arani, Uday R. Popat, Courtney D. DiNardo, Naval Daver, Musa Yilmaz, Hussein A. Abbas, Nicholas Short, Ghayas C. Issa, Elias Jabbour, Sherry A. Pierce, Julianne Chen, Ricky Garcia, Marina Konopleva, Guillermo Garcia-Manero, Amin M. Alousi, Elizabeth J. Shpall, Richard E. Champlin, Gautam Borthakur, Farhad Ravandi, Tapan M. Kadia
Journal: Blood
Blood (2022) 140 (Supplement 1): 4872–4875.
https://doi.org/10.1182/blood-2022-162962
Published: 2022
Journal Articles

A Phase I/II Study of Combination of ASTX727, Gilteritinib and Venetoclax in Patients with Relapsed/Refractory FLT3 Mutated Acute Myeloid Leukemia (AML) and Frontline FLT3 Mutated AML Patients Unfit for Chemotherapy

Faustine Ong, Nicholas Short, Naval Daver, Tapan M. Kadia, Courtney D. DiNardo, Musa Yilmaz, Yesid Alvarado, Kenneth Vaughan, Sherry A. Pierce, Hagop Kantarjian, Guillermo Garcia-Manero, Farhad Ravandi
Journal: Blood
Blood (2022) 140 (Supplement 1): 9029–9031.
https://doi.org/10.1182/blood-2022-159110
Published: 2022
Journal Articles

Clinical and Molecular Profiling of AML Patients with Chromosome 7 or 7q Deletions Incontext of TP53 Alterations and Venetoclax Treatment

Hussein A Abbas, Edward Ayoub, Hanxiao Sun, Rashmi Kanagal-Shamanna, Nicholas Short, Ghayas C. Issa, Musa Yilmaz, Sherry A. Pierce, Daniel Rivera, Brent Cham, Shane Wing, Ziyi Li, Danielle Hammond, Elias Jabbour, Gautam Borthakur, Guillermo Garcia-Manero, Michael Andreeff, Naval Daver, Tapan M. Kadia, Marina Konopleva, Courtney D. DiNardo, Farhad Ravandi
Journal: Blood
Blood (2022) 140 (Supplement 1): 6064–6066.
https://doi.org/10.1182/blood-2022-170458
Published: 2022
Journal Articles

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Long-Term Outcomes and Novel Observations from a Large BPDCN Cohort

Naveen Pemmaraju, Hagop Kantarjian, Joseph D. Khoury, Nitin Jain, Muzaffar H Qazilbash, Sanam Loghavi, Sherry A. Pierce, Keyur P. Patel, Guillermo Garcia-Manero, Elias Jabbour, Naval Daver, Gautam Borthakur, Marina Konopleva
Journal: Blood
Blood (2022) 140 (Supplement 1): 1293–1294.
https://doi.org/10.1182/blood-2022-170956
Published: 2022
Journal Articles

Impact of Spliceosome Mutations on the Prognosis of Myelodysplastic Syndrome (MDS)

Samuel Urrutia, Koji Sasaki, Rashmi Kanagal-Shamanna, Alex Bataller, Guillermo Montalban-Bravo, Irene Ganan-Gomez, Yue Wei, Hui Yang, Kelly S. Chien, Danielle Hammond, Carlos E. Bueso-Ramos, Sherry A. Pierce, Hagop Kantarjian, Guillermo Garcia-Manero
Journal: Blood
Blood (2022) 140 (Supplement 1): 6952–6954.
https://doi.org/10.1182/blood-2022-165488
Published: 2022
Journal Articles

Del5q with One Additional Cytogenetic Abnormality Other Than Del20q Identifies a Higher Risk Population of MDS Patients

Robert E. Briski, Kelly S. Chien, Guillermo Montalban-Bravo, Tapan M. Kadia, Elias Jabbour, Naveen Pemmaraju, Koji Sasaki, Danielle Hammond, Nicholas Short, Farhad Ravandi, Yesid Alvarado, Sherry A. Pierce, Guillermo Garcia-Manero, Hagop Kantarjian
Journal: Blood
Blood (2022) 140 (Supplement 1): 4042–4044.
https://doi.org/10.1182/blood-2022-170029
Published: 2022
Journal Articles

Evaluation of Emergent FLT3 Mutations (FLT3m) at Relapse in Patients (Pts) with Wild-Type FLT3 Acute Myeloid Leukemia (AML)

Fadi Haddad, Georgio Medawar, Rashmi Kanagal-Shamanna, Hector Alvarez, Sanam Loghavi, Naval Daver, Sherry A. Pierce, Elias Jabbour, Tapan M. Kadia, Nicholas Short, Courtney D. DiNardo, Gautam Borthakur, Hussein A Abbas, Naveen Pemmaraju, Guillermo Garcia-Manero, Farhad Ravandi, Hagop Kantarjian, Musa Yilmaz
Journal: Blood
Blood (2022) 140 (Supplement 1): 3196–3198.
https://doi.org/10.1182/blood-2022-169991
Published: 2022